Abstract: Despite the fact that 85% of bariatric operations are performed in women, the effects of the reproductive axis function on outcome of bariatric surgery remain to be determined. Here we developed the first published model of Roux-en-Y gastric bypass (RYGB) in female rats. We show in ovariectomized rats receiving estradiol or control treatment that (1) RYGB-induced body weight loss and (2) the satiating efficacy of endogenous glucagon-like peptide-1 and cholecystokinin satiation were significantly increased in estradiol-treated rats. These data are relevant to the care of obese women, in particular perimenopausal women, undergoing bariatric surgery. Author contributions: LA (study concept and design; acquisition, analysis and interpretation of data; surgery; drafted the manuscript), KA (acquisition of data; surgery; interpretation of data; critical review of the manuscript), NG (study concept and design;interpretation of data; critical review of the manuscript), MS (critical review of the manuscript), TAL (study concept and design; interpretation of data; critical review of the manuscript), MB (study concept and design; surgery; interpretation of data; critical review of the manuscript).
Abstract
Despite the fact that ∼85% of bariatric operations are performed in women, the effects of the reproductive-axis function on bariatric surgery outcome remain to be determined.
Here we developed the first published model of Roux-en-Y gastric bypass (RYGB) in female rats. We show in ovariectomized rats receiving estradiol or control treatment, that
(1) RYGB-induced body-weight loss and (2) the satiating efficacy of endogenous glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK) satiation were significantly increased in estradiol-treated rats. These data are relevant to the care of obese women, in particular peri-menopausal women undergoing bariatric surgery.
Bariatric surgery is currently the most effective treatment for morbid obesity.
Morbid obesity (BMI > 40 m/kg
2 ) is more prevalent in women than in men 4, 8 , and the adverse effects of obesity on psychological well-being are more pronounced in women 5 .
Correspondingly, more than 85% of patients undergoing bariatric surgery are female 9 .
Despite the well-known effects of normal reproductive-axis function on eating and body Finally, the acute effects of Exendin (9-39) and Devazepide on Ensure intake were tested (Phase 4).
At arrival, rats weighed 185±6 g. During Phase 1, rats gained ∼60 g, reaching an
overall mean preoperative body weight of 247±3 g ( Figure 1A ). versus 49 g in RYGB-OIL rats and -1 g in RYGB-E2 rats.
RYGB and estradiol treatment had similar effects on energy intake as on body weight both during Phase 2, when rats were fed solid, high-energy diet, and during Phase 3, when the rats were fed Ensure, which increased energy intake in all groups, ( Figure 1B ). RYGB-OIL rats ate less than SHAM-OIL rats in both Phases, RYGB-E2 rats ate less than RYGB-OIL in Phase 2 and tended to eat less in Phase 3 (P < 0.06), and SHAM-E2 rats ate less than SHAM-OIL rats in both Phases. RYGB also reduced the ratsʼ selection of both test diets vs. chow (Supplementary Table 1 ).
We tested the effects of Exendin (9-39) and Devazepide, which are potent and selective receptor antagonists of GLP-1 and CCK, respectively, during 60-min Ensure tests (Phase 4). In both sham-operated and RYGB rats, the antagonistsʼ eatingstimulatory effects were significantly greater in estradiol-treated than oil-treated rats ( Figure 2 ). In neither case, however, was the antagonist effect greater in RYGB-E2 rats than in SHAM-E2 rats.
We consider three aspects of our data important. First, to our knowledge, this is the first study investigating the influence of reproductive-axis function on bariatricsurgery outcome. These data are critical because the great majority of gastric bypass operations are performed in women and because the reproductive axis, in particular estrogens, potently influence the physiology of eating and body-weight control. Second, we showed that estradiol significantly increased RYGBʼs potency to reduce weight gain and to inhibit eating. Similar effects were obtained when RYGB rats were fed a highenergy solid diet (Phase 2) and Ensure, a 57%-energy/sugar liquid diet (Phase 3), suggesting that they do not depend on particular dietary forms or components. Our data suggest that RYGB may be more effective in healthy premenopausal women than in postmenopausal women who do not receive hormone-replacement therapy or in women with reduced estrogen levels, such as patients with polycystic ovary syndrome 7 . We are not aware of any clinical studies assessing this question, although we found recently that bariatric surgery was more effective in postmenopausal-age women than premenopausal-age women (Ochner, Geary and Asarian, unpublished). Whether estrogens enhance the eating and body-weight lowering effects of RYGB via the same mechanisms by which they contribute to the normal control of eating and body weight also deserves further research. Furthermore, it is unclear whether estrogens affect the outcome of other types of bariatric surgery procedures, such as gastric banding or gastric sleeve resection. Third, we provide novel evidence that estrogens increase endogenous GLP-1 and CCK satiation in RYGB. In previous reports, estradiol increased CCK satiation in rats with intact intestines 1, 3, 6 . This is the first report that estradiol also increases GLP-1 satiation in intestine-intact rats and that estradiol increases the satiating effect of CCK and GLP-1 in RYGB rats. We did not, however, detect any 
